Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis.
Journal
Targeted oncology
ISSN: 1776-260X
Titre abrégé: Target Oncol
Pays: France
ID NLM: 101270595
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
accepted:
03
02
2022
pubmed:
1
3
2022
medline:
13
4
2022
entrez:
28
2
2022
Statut:
ppublish
Résumé
Information on the epidemiology of uncommon EGFR mutations including exon 20 insertions amongst non-small-cell lung cancer (NSCLC) is lacking. The objective of this pragmatic literature review (PLR) and meta-analysis was to generate robust prevalence and incidence estimates based on ranges of exon 20 insertion mutations reported in the literature. Searches of MEDLINE, Embase, congresses and reference lists for articles published from 2013 in key European countries of interest (Belgium, France, Germany, Italy, The Netherlands, Spain, Sweden, Switzerland, United Kingdom) were performed. Articles were reviewed against pre-specified criteria and their quality was appraised using a published checklist. Prevalence estimates were synthesised by random-effects meta-analyses. Eighty unique studies of moderate-to-high quality were included in the PLR. The meta-analysed prevalence for EGFR mutations was 12.5% (95% confidence interval [CI]: 11.0, 14.1) in any stage NSCLC and 14.8% (12.8, 17.1) in advanced/metastatic NSCLC. The prevalence of exon 20 insertions was 0.7% (0.4, 1.1) in any stage NSCLC and 6.1% (4.0, 9.4) in any stage EGFR-positive NSCLC. Mutation status was primarily measured using direct sequencing or a combination of methods. One study reporting exon 20 insertions in advanced/metastatic disease was identified, which reported a prevalence of 0.5% in overall NSCLC and 4.0% in EGFR-positive NSCLC. EGFR exon 20 insertion mutations are rare in NSCLC. There is a high unmet need in patients with exon 20 insertions, including effective therapies. Prospective cohort studies are needed to better clinically characterise these patients.
Sections du résumé
BACKGROUND
Information on the epidemiology of uncommon EGFR mutations including exon 20 insertions amongst non-small-cell lung cancer (NSCLC) is lacking.
OBJECTIVE
The objective of this pragmatic literature review (PLR) and meta-analysis was to generate robust prevalence and incidence estimates based on ranges of exon 20 insertion mutations reported in the literature.
MATERIALS AND METHODS
Searches of MEDLINE, Embase, congresses and reference lists for articles published from 2013 in key European countries of interest (Belgium, France, Germany, Italy, The Netherlands, Spain, Sweden, Switzerland, United Kingdom) were performed. Articles were reviewed against pre-specified criteria and their quality was appraised using a published checklist. Prevalence estimates were synthesised by random-effects meta-analyses.
RESULTS
Eighty unique studies of moderate-to-high quality were included in the PLR. The meta-analysed prevalence for EGFR mutations was 12.5% (95% confidence interval [CI]: 11.0, 14.1) in any stage NSCLC and 14.8% (12.8, 17.1) in advanced/metastatic NSCLC. The prevalence of exon 20 insertions was 0.7% (0.4, 1.1) in any stage NSCLC and 6.1% (4.0, 9.4) in any stage EGFR-positive NSCLC. Mutation status was primarily measured using direct sequencing or a combination of methods. One study reporting exon 20 insertions in advanced/metastatic disease was identified, which reported a prevalence of 0.5% in overall NSCLC and 4.0% in EGFR-positive NSCLC.
CONCLUSIONS
EGFR exon 20 insertion mutations are rare in NSCLC. There is a high unmet need in patients with exon 20 insertions, including effective therapies. Prospective cohort studies are needed to better clinically characterise these patients.
Identifiants
pubmed: 35226283
doi: 10.1007/s11523-022-00868-z
pii: 10.1007/s11523-022-00868-z
pmc: PMC8995294
doi:
Substances chimiques
Protein Kinase Inhibitors
0
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
153-166Informations de copyright
© 2022. The Author(s).
Références
Ferlay J, Colombet M, Soerjomataram I, Siegel R, Torre L, Jemal A. Global and regional estimates of the incidence and mortality for 38 cancers: GLOBOCAN 2018. World Health Organization, International Agency for Research on Cancer: Lyon, France. 2018.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
Eurostat. Cancer statistics - specific cancers 2020. https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Cancer_statistics_-_specific_cancers#Lung_cancer . Accessed 21 May 2021.
National Cancer Institute Surveillance Epidemiology and End Results Program. Percent distribution and counts by histology among histologically confirmed cases, 2013–2017 both sexes by race 2017. https://seer.cancer.gov/archive/csr/1975_2017/results_single/sect_15_table.28.pdf . Accessed 18 January 2022.
Zhu Q-G, Zhang S-M, Ding X-X, He B, Zhang H-Q. Driver genes in non-small cell lung cancer: characteristics, detection methods, and targeted therapies. Oncotarget. 2017;8(34):57680.
doi: 10.18632/oncotarget.17016
pmcid: 5593676
pubmed: 28915704
Pikor LA, Ramnarine VR, Lam S, Lam WL. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 2013;82(2):179–89.
doi: 10.1016/j.lungcan.2013.07.025
pubmed: 24011633
Bergethon K, Shaw AT, Ignatius Ou S-H, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863–70.
doi: 10.1200/JCO.2011.35.6345
pmcid: 3295572
pubmed: 22215748
Lynch TJBD, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.
doi: 10.1056/NEJMoa040938
pubmed: 15118073
Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 2017;9(5):52.
doi: 10.3390/cancers9050052
pmcid: 5447962
Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2010;2(1):48–51.
pubmed: 22263017
pmcid: 3256436
Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985–93.
doi: 10.18632/oncotarget.12587
pmcid: 5346692
pubmed: 27738317
Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339–46.
doi: 10.1093/jnci/dji055
pubmed: 15741570
Brindel A, Althakfi W, Barritault M, Watkin E, Maury J-M, Bringuier P-P, et al. Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors. J Thorac Dis. 2020;12(9):4643–50.
doi: 10.21037/jtd-19-3790
pmcid: 7578497
pubmed: 33145037
Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther. 2019;4(1):1–10.
doi: 10.1038/s41392-019-0038-9
Yasuda H, Park E, Yun C-H, Sng NJ, Lucena-Araujo AR, Yeo W-L, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013;5(216):216ra177.
Wang F, Li C, Wu Q, Lu H. EGFR exon 20 insertion mutations in non-small cell lung cancer. Transl Cancer Res. 2020;9(4):2982–91.
doi: 10.21037/tcr.2020.03.10
pmcid: 8799012
pubmed: 35117654
Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 2013;66(2):79–89.
doi: 10.1136/jclinpath-2012-201194
pubmed: 23172555
Illumina. Advantages of next-generation sequencing vs. qPCR 2021. https://www.illumina.com/science/technology/next-generation-sequencing/ngs-vs-qpcr.html . Accessed 29 July 2021.
Sousa AC, Silveira C, Janeiro A, Malveiro S, Oliveira AR, Felizardo M, et al. Detection of rare and novel EGFR mutations in NSCLC patients: implications for treatment-decision. Lung Cancer. 2020;139:35–40.
doi: 10.1016/j.lungcan.2019.10.030
pubmed: 31715539
Xie T, Zou Z, Liu C, Zhu Y, Xu Z, Wang L, et al. Front-line therapy in EGFR exon 19 deletion and 21 Leu858Arg mutations in advanced non-small cell lung cancer: a network meta-analysis. Evid Based Complem Altern Med. 2021;2021:1–15.
Yasuda H, Ichihara E, Sakakibara-Konishi J, Zenke Y, Takeuchi S, Morise M, et al. A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. Lung Cancer. 2021;162:140–6.
doi: 10.1016/j.lungcan.2021.10.006
pubmed: 34808485
Le X, Goldman JW, Clarke JM, Tchekmedyian N, Piotrowska Z, Chu D, et al. Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients. J Clin Oncol. 2020;38(15_suppl):9514.
doi: 10.1200/JCO.2020.38.15_suppl.9514
Burnett H, Emich H, Carroll C, Stapleton N, Mahadevia P, Li T. Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. PLoS ONE. 2021;16(3):e0247620.
doi: 10.1371/journal.pone.0247620
pmcid: 7939356
pubmed: 33684140
Nicolas Girard LB, Minchom A, Ignatius Ou S-H, Gadgeel S, Trigo J, Viteri S, Li G, Mahadevia P, Londhe A, Backenroth D, Li T, Bauml T, editor. Comparative clinical outcomes for patients with NSCLC harbouring EGFR exon 20 insertion mutations and common EGFR mutations. In: 2020 World conference on lung cancer; 2020; Singapore 2020.
U.S Food & Drug Administration. FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer 2021. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-amivantamab-vmjw-metastatic-non-small-cell-lung-cancer . Accessed 18 January 2022.
European Medicines Agency. Rybrevant Opinion 2021. https://www.ema.europa.eu/en/medicines/human/summaries-opinion/rybrevant . Accessed 18 January 2022.
U.S Food & Drug Administration. FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations 2021. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mobocertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20 . Accessed 18 January 2022.
Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.
doi: 10.1136/bmj.j4008
pmcid: 5833365
pubmed: 28935701
Joanna Briggs Institute. The Joanna Briggs Institute Critical Appraisal tools for us in JBI systematic reviews checklist for prevalence studies. 2017. University of Adelaide, Australia. https://jbi.global/sites/default/files/2019-05/JBI_Critical_Appraisal-Checklist_for_Diagnostic_Test_Accuracy_Studies2017_0.pdf . Accessed 29 July 2020.
Team RC. R: a language and environment for statistical computing. 2013.
Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153–60.
doi: 10.1136/ebmental-2019-300117
pubmed: 31563865
Beau-Faller M, Prim N, Ruppert AM, Nanni-Metellus I, Lacave R, Lacroix L, et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol. 2014;25(1):126–31.
doi: 10.1093/annonc/mdt418
pubmed: 24285021
Mansuet-Lupo A, Zouiti F, Alifano M, Tallet A, Charpentier M-C, Ducruit V, et al. Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis? J Trans Med. 2014;12(1):131.
doi: 10.1186/1479-5876-12-131
Mansuet-Lupo A, Bobbio A, Blons H, Becht E, Ouakrim H, Didelot A, et al. The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort. Chest. 2014;146(3):633–43.
doi: 10.1378/chest.13-2499
pubmed: 24676429
Locatelli-Sanchez M, Couraud S, Arpin D, Riou R, Bringuier PP, Souquet PJ. Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18–21 sequencing results of 753 patients and subsequent clinical outcomes. Lung. 2013;191(5):491–9.
doi: 10.1007/s00408-013-9482-4
pubmed: 23749122
Stella GM, Scabini R, Inghilleri S, Cemmi F, Corso S, Pozzi E, et al. EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells. J Cancer Res Clin Oncol. 2013;139(8):1327–35.
doi: 10.1007/s00432-013-1444-y
pubmed: 23644698
Moore DA, Balbi K, Ingham A, Arkenau HT, Bennett P. Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice. J Clin Pathol. 2018;71(11):1001–6.
doi: 10.1136/jclinpath-2018-205319
pubmed: 30054375
Evans M, O’Sullivan B, Smith M, Hughes F, Mullis T, Trim N, et al. Large-scale EGFR mutation testing in clinical practice: analysis of a series of 18,920 non-small cell lung cancer cases. Pathol Oncol Res. 2019;25(4):1401–9.
doi: 10.1007/s12253-018-0460-2
pubmed: 30094734
Kerner GS, Schuuring E, Sietsma J, Hiltermann TJ, Pieterman RM, de Leede GP, et al. Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome. PLoS ONE. 2013;8(7):e70346.
doi: 10.1371/journal.pone.0070346
pmcid: 3726644
pubmed: 23922984
Sandelin M, Berglund A, Sundstrom M, Micke P, Ekman S, Bergqvist M, et al. Patients with non-small cell lung cancer analyzed for EGFR: adherence to guidelines, prevalence and outcome. Anticancer Res. 2015;35(7):3979–86.
pubmed: 26124345
Vazquez S, Casal J, Afonso FJA, Firvida JL, Santome L, Baron F, et al. EGFR testing and clinical management of advanced NSCLC: A galician lung cancer group study (GGCP 048–10). Cancer Manag. 2016;8:11–20.
doi: 10.3390/cancers8010011
Chouaid C, Filleron T, Debieuvre D, Pérol M, Girard N, Dansin E, et al. A real-world study of patients with advanced non-squamous non-small cell lung cancer with EGFR exon 20 insertion: clinical characteristics and outcomes. Target Oncol. 2021;16(6):801–11.
doi: 10.1007/s11523-021-00848-9
pubmed: 34661827
Gutiérrez L, Royuela A, Carcereny E, López-Castro R, Rodríguez-Abreu D, Massuti B, et al. Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data. BMC Cancer. 2021;21(1):1–11.
doi: 10.1186/s12885-021-08713-8